X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2560) 2560
Publication (222) 222
Newsletter (85) 85
Book Review (68) 68
Book Chapter (11) 11
Conference Proceeding (3) 3
Dissertation (3) 3
Paper (2) 2
Book / eBook (1) 1
Newspaper Article (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1609) 1609
erythromycin (1432) 1432
pharmacology & pharmacy (1095) 1095
male (974) 974
female (779) 779
adult (676) 676
animals (638) 638
pharmacokinetics (571) 571
erythromycin - pharmacology (535) 535
index medicus (524) 524
anti-bacterial agents - pharmacology (478) 478
erythromycin - pharmacokinetics (467) 467
drug interactions (434) 434
azithromycin (416) 416
middle aged (375) 375
microbiology (370) 370
clarithromycin (359) 359
erythromycin - analogs & derivatives (343) 343
anti-bacterial agents - pharmacokinetics (337) 337
antibiotics (329) 329
macrolides (310) 310
erythromycin - administration & dosage (288) 288
administration, oral (287) 287
infectious diseases (276) 276
anti-bacterial agents - therapeutic use (272) 272
microbial sensitivity tests (269) 269
erythromycin - therapeutic use (246) 246
aged (241) 241
cytochrome p-450 enzyme system - metabolism (224) 224
anti-bacterial agents - administration & dosage (216) 216
cytochrome p-450 cyp3a (216) 216
area under curve (203) 203
metabolism (203) 203
erythromycin breath test (190) 190
rats (187) 187
adolescent (186) 186
macrolide antibiotics (183) 183
dose-response relationship, drug (155) 155
in-vitro (155) 155
anti-bacterial agents - adverse effects (153) 153
time factors (153) 153
cross-over studies (152) 152
half-life (151) 151
biological availability (145) 145
kinetics (144) 144
erythromycin - blood (142) 142
macrolide (142) 142
research (135) 135
erythromycin - adverse effects (134) 134
analysis (133) 133
mice (133) 133
erythromycin - metabolism (132) 132
double-blind method (128) 128
p-glycoprotein (123) 123
veterinary sciences (122) 122
child (116) 116
azithromycin - pharmacology (110) 110
roxithromycin (110) 110
midazolam (108) 108
anti-bacterial agents - chemistry (106) 106
tissue distribution (106) 106
chromatography, high pressure liquid (102) 102
drugs (102) 102
resistance (101) 101
cytochrome p-450 enzyme inhibitors (100) 100
research article (99) 99
toxicology (99) 99
medicine & public health (98) 98
pharmacology (98) 98
anti-bacterial agents - blood (97) 97
chemistry, medicinal (92) 92
pharmacology/toxicology (92) 92
azithromycin - pharmacokinetics (91) 91
clarithromycin - pharmacology (91) 91
drug-interactions (90) 90
treatment outcome (90) 90
in vitro techniques (89) 89
streptococcus pneumoniae - drug effects (89) 89
therapy (89) 89
drug resistance, bacterial (87) 87
immunology (87) 87
drug administration schedule (86) 86
azithromycin - therapeutic use (84) 84
antibacterial activity (82) 82
biochemistry & molecular biology (82) 82
health aspects (81) 81
infection (81) 81
bacterial infections - drug therapy (80) 80
clarithromycin - pharmacokinetics (80) 80
drug resistance, microbial (80) 80
drug therapy (80) 80
efficacy (80) 80
ketolides (80) 80
respiratory tract infections - drug therapy (79) 79
aged, 80 and over (78) 78
pneumonia (78) 78
bioavailability (77) 77
child, preschool (76) 76
cytochrome p-450 (76) 76
liver - metabolism (76) 76
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2559) 2559
French (25) 25
Japanese (24) 24
German (16) 16
Russian (12) 12
Spanish (5) 5
Chinese (4) 4
Italian (3) 3
Polish (3) 3
Bulgarian (1) 1
Croatian (1) 1
Dutch (1) 1
Finnish (1) 1
Hungarian (1) 1
Korean (1) 1
Portuguese (1) 1
Romanian (1) 1
Slovenian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The American Journal of Cardiology, ISSN 0002-9149, 2004, Volume 94, Issue 9, pp. 1140 - 1146
Three-hydroxy-3-methylglutaryl coenzyme-A reductase inhibitors (statins) are first-line treatments for hypercholesterolemia. Although exceedingly well... 
CLARITHROMYCIN | INDUCED RHABDOMYOLYSIS | LOVASTATIN | CARDIAC & CARDIOVASCULAR SYSTEMS | CONCOMITANT USE | ERYTHROMYCIN | FATAL RHABDOMYOLYSIS | ITRACONAZOLE | ROSUVASTATIN | DRUG-INTERACTION | CYCLOSPORINE | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Pyrroles - pharmacokinetics | Cytochrome P-450 Enzyme Inhibitors | Cytochrome P-450 Enzyme System - administration & dosage | Area Under Curve | Heptanoic Acids - pharmacokinetics | Humans | Middle Aged | Mibefradil - pharmacokinetics | Male | Protein Synthesis Inhibitors - administration & dosage | Verapamil - administration & dosage | Dose-Response Relationship, Drug | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Antiprotozoal Agents - pharmacokinetics | Drug Interactions | Itraconazole - pharmacokinetics | Pyrroles - administration & dosage | Clarithromycin - pharmacokinetics | Mibefradil - administration & dosage | Clarithromycin - administration & dosage | Heptanoic Acids - administration & dosage | Adult | Female | Itraconazole - administration & dosage | Drug Therapy, Combination | Double-Blind Method | Simvastatin - administration & dosage | Verapamil - pharmacokinetics | Biomarkers - blood | Simvastatin - pharmacokinetics | Protein Synthesis Inhibitors - pharmacokinetics | Atorvastatin Calcium | Anticholesteremic Agents - pharmacokinetics | Pravastatin - administration & dosage | Anticholesteremic Agents - administration & dosage | Adolescent | Antiprotozoal Agents - administration & dosage | Calcium Channel Blockers - administration & dosage | Creatine Kinase - drug effects | Calcium Channel Blockers - pharmacokinetics | Pravastatin - pharmacokinetics
Journal Article
Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, 10/2011, Volume 55, Issue 10, pp. 4619 - 4630
Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit... 
VITRO DYNAMIC-MODEL | STREPTOCOCCUS-PNEUMONIAE | PHARMACODYNAMIC MODEL | POPULATION PHARMACOKINETICS | PSEUDOMONAS-AERUGINOSA | ADAPTIVE RESISTANCE | IN-VIVO | MICROBIOLOGY | PHARMACOLOGY & PHARMACY | MONTE-CARLO SIMULATIONS | AMINOGLYCOSIDE ANTIBIOTICS | RESPIRATORY-TRACT INFECTIONS | Fluoroquinolones | Aza Compounds - pharmacokinetics | Area Under Curve | Erythromycin - pharmacology | Escherichia coli - drug effects | Humans | Cefuroxime - pharmacology | Aza Compounds - pharmacology | Quinolines - pharmacology | Microbial Sensitivity Tests | Quinolines - pharmacokinetics | Anti-Bacterial Agents - therapeutic use | Gentamicins - pharmacology | Computer Simulation | Vancomycin - pharmacology | Streptococcus pyogenes - drug effects | Gentamicins - pharmacokinetics | Penicillin G - pharmacology | Erythromycin - pharmacokinetics | Cefuroxime - pharmacokinetics | Vancomycin - pharmacokinetics | Anti-Bacterial Agents - pharmacokinetics | Anti-Bacterial Agents - pharmacology | Anti-Bacterial Agents - administration & dosage | Penicillin G - pharmacokinetics | Drugs | Subpopulations | Pharmacodynamics | Gentamicin | Benzylpenicillin | Erythromycin | Moxifloxacin | Regression analysis | Vancomycin | Drug development | Cefuroxime | Antibiotics | Minimum inhibitory concentration | Models | Pharmacokinetics | Experimental Therapeutics
Journal Article
British Journal of Clinical Pharmacology, ISSN 0306-5251, 09/2013, Volume 76, Issue 3, pp. 455 - 466
Aims The anticoagulant rivaroxaban is an oral, direct Factor Xa inhibitor for the management of thromboembolic disorders. Metabolism and excretion involve... 
P‐glycoprotein | rivaroxaban | drug interactions | cytochrome P450 | healthy subjects | P-glycoprotein | Rivaroxaban | Healthy subjects | Cytochrome P450 | Drug interactions | BAY-59-7939 | SAFETY | PREVENTION | PHARMACODYNAMICS | PROTEASE INHIBITORS | IN-VITRO | FACTOR-XA INHIBITOR | ERYTHROMYCIN | PHARMACOLOGY & PHARMACY | LIVER-MICROSOMES | Anticoagulants - administration & dosage | Cytochrome P-450 Enzyme Inhibitors | Erythromycin - pharmacology | Ketoconazole - administration & dosage | Humans | Middle Aged | Cytochrome P-450 Enzyme System - metabolism | Midazolam - administration & dosage | Substrate Specificity | Metabolic Clearance Rate | Thiophenes - administration & dosage | Ketoconazole - pharmacology | Enzyme Inhibitors - administration & dosage | Young Adult | Drug Interactions | Enzyme Inhibitors - pharmacokinetics | Clarithromycin - pharmacokinetics | Clarithromycin - administration & dosage | Adult | Morpholines - administration & dosage | Enzyme Inhibitors - pharmacology | Ketoconazole - pharmacokinetics | Midazolam - pharmacokinetics | Cytochrome P-450 CYP3A - administration & dosage | Erythromycin - administration & dosage | ATP Binding Cassette Transporter, Subfamily B, Member 1 - antagonists & inhibitors | ATP Binding Cassette Transporter, Subfamily B, Member 1 - metabolism | Thiophenes - pharmacokinetics | Erythromycin - pharmacokinetics | Cytochrome P-450 CYP3A - metabolism | Adolescent | Anticoagulants - pharmacokinetics | Morpholines - pharmacokinetics | Clarithromycin - pharmacology | Midazolam - pharmacology | Ketoconazole | Protease inhibitors | Fluconazole | Proteases | Cytochrome P-450 | Dosage and administration | Anticoagulants (Medicine) | Erythromycin | Thromboembolism
Journal Article
The Journal of Clinical Pharmacology, ISSN 0091-2700, 09/2015, Volume 55, Issue 9, pp. 1012 - 1023
Journal Article
Journal Article
Journal Article
CLINICAL PHARMACOKINETICS, ISSN 0312-5963, 2002, Volume 41, Issue 5, pp. 329 - 342
Gender-related differences in pharmacokinetics have frequently been considered as potentially important determinants for the clinical effectiveness of drug... 
ERYTHROMYCIN BREATH TEST | ORAL-CONTRACEPTIVE STEROIDS | INTERINDIVIDUAL VARIABILITY | TIRILAZAD MESYLATE | FREE-RADICAL SCAVENGER | PHARMACOLOGY & PHARMACY | HUMAN LIVER | PROTEIN-BINDING | THIOPURINE METHYLTRANSFERASE ACTIVITY | HEALTHY-VOLUNTEERS | P-GLYCOPROTEIN
Journal Article
Journal of Pharmaceutical Sciences, ISSN 0022-3549, 09/2013, Volume 102, Issue 9, pp. 2889 - 2894
Journal Article
British Journal of Clinical Pharmacology, ISSN 0306-5251, 12/2016, Volume 82, Issue 6, pp. 1591 - 1600
Journal Article